BioCryst Pharmaceuticals' (BCRX) Buy Rating Reiterated at Needham & Company LLC

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research note issued to investors on Thursday, Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock, down from their previous price objective of $14.00. Needham & […]

Related Keywords

United States ,America ,Machelle Sanders ,Fairfield Bush ,Biocryst Pharmaceuticals ,Analyst Recommendations For Biocryst Pharmaceuticals ,Biocryst Pharmaceuticals Price Performance ,News Ratings For Biocryst Pharmaceuticals Daily ,Biocryst Pharmaceuticals Company Profile ,Biocryst Pharmaceuticals Inc ,Advisory Services Network ,Needham Company ,Institutional Investors Weigh In On Biocryst Pharmaceuticals ,Lazard Asset Management ,Get Free Report ,Cryst Pharmaceuticals ,Director Machelle Sanders ,Services Network ,Biocryst Pharmaceuticals Daily ,